Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma

Launched by INTECH BIOPHARM LTD. · May 28, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at two different types of inhalers that contain albuterol, a medication commonly used to treat mild asthma. The goal is to see if these inhalers work the same way in people with stable mild asthma. Participants will undergo a test that helps measure how their lungs respond to medication. They will be asked to use either the test inhaler or a well-known reference inhaler, ProAir HFA, and then their lung function will be assessed.

To join the study, participants must be between 20 and 65 years old and have a confirmed diagnosis of mild asthma. They should have been using specific asthma medications regularly for at least a month and must be in good overall health, with no recent respiratory infections or major health issues. Those who qualify will be required to provide consent and may need to adhere to certain guidelines throughout the trial. Participants can expect to undergo tests that measure their lung capacity and responsiveness to the inhalers, while being closely monitored for their health and safety during the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male, non-pregnant and non-lactating female subjects (20-65 years of age, inclusive).
• • 2. A clinical diagnosis of mild asthma with historical documentation of the asthma diagnosis according to either: (1) the National Asthma Education and Prevention Program (NAEPP) guidelines (2007) or (2) the Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention (2020).
• • 3. Stable mild asthma receiving the following required inhaled medications for at least 1 month prior to screening: Low doses of ICS alone, or in combination with SABA, used regularly with a stable regimen.
• • 4. Forced Expiratory Volume in 1 second (FEV1) ≥ 80% of the local predicted normal value after withholding SABA ≥ 8 hours.
• • 5. Airway responsiveness to methacholine demonstrated by a pre-albuterol-dose (baseline) PC20 ≤ 8 mg/mL.
• • 6. Nonsmoker for at least 6 months prior to the study and a maximum smoking history of 5 pack-years (the equivalent of one pack per day for 5 years).
• • 7. Provision of written informed consent.
• • 8. Other than asthma, in general good health.
• • 9. Body mass index (BMI) between 17 and 35 kg/m2 (inclusive).
• • 10. Able to correctly use MDI inhalers.
• • 11. Able to perform valid and reproducible pulmonary function tests including no evidence of spirometry effort-induced bronchoconstriction.
• • 12. If the subject or subject's partner is of child-bearing potential, a medically acceptable form of contraception will be used for the duration of the study. Medically acceptable contraceptives include: (1) surgical sterilization, (2) Health Authority approved female hormonal contraceptives, (3) an intrauterine device (IUD), (4) condoms with spermicide, or (5) diaphragm with spermicide.
• Exclusion Criteria:
• • 1. Evidence of conditions altering airway reactivity to methacholine, including upper or lower respiratory tract infections (e.g., pneumonia, viral bronchitis, allergic rhinitis, sinobronchitis, etc.) within 6 weeks before Screening.
• • 2. Evidence of a baseline FEV1 \< 60% of the local predicted normal value or FEV1 \< 1.5 L.
• • 3. History of seasonal asthma exacerbations, in which case the subject should be studied outside of the relevant allergen season.
• • 4. History of cystic fibrosis, bronchiectasis, COPD, or other respiratory diseases including COPD, chronic bronchitis, emphysema, tuberculosis, pulmonary carcinoma, pulmonary fibrosis, pulmonary hypertension that, in the opinion of the Investigator, would compromise subject safety or interfere with the evaluations.
• • 5. History of cardiovascular, hematological, renal, neurologic, hepatic, psychiatric, endocrine dysfunction, including ECG with evidence of ischemic heart diseases and significant arrhythmias.
• • 6. Treatment in an emergency room or hospitalization for acute asthmatic symptoms within 3 months prior to screening.
• • 7. Known intolerance or hypersensitivity to any component of the albuterol MDI, beta2 receptor-agonist drug, HFA, any related compounds or methacholine.
• • 8. Need for daily oral corticosteroids within 3 months prior to screening.
• • 9. Cardiac arrhythmia or 12-lead electrocardiogram (ECG) abnormalities, that in the opinion of the Investigator would compromise subject safety or interfere with the evaluations, or a QTc \> 440 ms for males and \> 460 ms for females using Fredericia formula.
• • 10. Subjects receiving beta blocker via any route or who may require beta blockers during the study.
• • 11. History of narrow angle glaucoma, convulsive disorders, hyperthyroidism, uncontrolled diabetes, paradoxical bronchospasm.
• • 12. History of malignancies.
• • 13. History of alcohol or drug abuse.
• • 14. Eye, brain, thoracic, and abdominal surgeries within 3 months prior to screening.
• • 15. Use of cromyolyn, leukotriene receptor antagonists (LTRA), nedocromil, zileuton, theophylline, or long-acting beta-agonists (LABA) within 1 month prior to screening.
• • 16. History of receiving muscarinic beta2-agonists (MABAs), short-acting muscarinic antagonists (SAMAs), long-acting muscarinic antagonists (LAMAs), anti-IgE, anti-IL5/5R, anti-IL4R, high dose ICS, or systemic corticosteroid for treatment of asthma within 6 months prior to screening.
• • 17. Known Human Immunodeficiency Virus (HIV)-positive status.
• • 18. Participated in any interventional clinical trials within 1 month prior to screening.
• • 19. Pregnancy or breast feeding.